tetano
Editor, Senior Moderator
Biol Blood Marrow Transplant. 2011 Feb 12. [Epub ahead of print]
Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.
Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, Serve H, Bickel M, Bug G.
.Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Germany.
Abstract
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after one or two doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients (ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by haemagglutination inhibition assay. Seroconversion was defined by either an AB titer of ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4 fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received one dose and 11 of these patients two doses of the vaccine. The rate of seroconversion was 41.2 % (95 % confidence interval (CI) 18.4-67.1) after the first and 81.8 % (95 % CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after one dose of the vaccine were more likely to receive any immunosuppressive agent (p=0.003), but time elapsed after or type of HSCT, age, sex or chronic graft versus host disease were not different when compared to patients with seroconversion. In patients with hematologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1 influenza A vaccine was poor, but increased after a second dose.
Copyright ? 2011. Published by Elsevier Inc.
PMID: 21324375 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21324375
Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.
Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, Serve H, Bickel M, Bug G.
.Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Germany.
Abstract
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after one or two doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients (ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by haemagglutination inhibition assay. Seroconversion was defined by either an AB titer of ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4 fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received one dose and 11 of these patients two doses of the vaccine. The rate of seroconversion was 41.2 % (95 % confidence interval (CI) 18.4-67.1) after the first and 81.8 % (95 % CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after one dose of the vaccine were more likely to receive any immunosuppressive agent (p=0.003), but time elapsed after or type of HSCT, age, sex or chronic graft versus host disease were not different when compared to patients with seroconversion. In patients with hematologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1 influenza A vaccine was poor, but increased after a second dose.
Copyright ? 2011. Published by Elsevier Inc.
PMID: 21324375 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21324375